Literature DB >> 10412014

The intrastratial injection of an adenosine A(2) receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease.

R Reggio1, A Pèzzola, P Popoli.   

Abstract

The influence of 3,7-dimethyl-1-propargylxanthine (DMPX) an adenosine A(2) receptor antagonist, was studied in the quinolinic acid (QA) model of Huntington's disease. Male Wistar rats received bilateral intrastriatal injections of QA (300 nmol) alone or plus DMPX (0.02, 0.2 and 2 microg). At the dose of 0.2 microg, DMPX completely prevented QA-induced EEG abnormalities at the level of frontal cortex. The results support the hypothesis of a neuroprotective role of adenosine A(2) receptor antagonists. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10412014     DOI： 10.1016/s0006-8993(99)01489-4

Source DB:  PubMed          Journal:  Brain Res        ISSN： 0006-8993            Impact factor:   3.252


  6 in total

Review 1.  Presynaptic modulation controlling neuronal excitability and epileptogenesis: role of kainate, adenosine and neuropeptide Y receptors.

Authors:  João O Malva; Ana P Silva; Rodrigo A Cunha
Journal:  Neurochem Res       Date:  2003-10       Impact factor: 3.996

Review 2.  The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.

Authors:  David Blum; Yijuang Chern; Maria Rosaria Domenici; Luc Buée; Chien-Yu Lin; William Rea; Sergi Ferré; Patrizia Popoli
Journal:  J Caffeine Adenosine Res       Date:  2018-06-01

3.  Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.

Authors:  Patrizia Popoli; Annita Pintor; Maria Rosaria Domenici; Claudio Frank; Maria Teresa Tebano; Antonella Pèzzola; Laura Scarchilli; Davide Quarta; Rosaria Reggio; Fiorella Malchiodi-Albedi; Mario Falchi; Marino Massotti
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

4.  Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity.

Authors:  Oscar P Dall'Igna; Lisiane O Porciúncula; Diogo O Souza; Rodrigo A Cunha; Diogo R Lara; Oscar P Dall'lgna
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

5.  Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade.

Authors:  Rodrigo A Cunha
Journal:  Purinergic Signal       Date:  2005-03-17       Impact factor: 3.765

Review 6.  Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.

Authors:  Ágatha Oliveira-Giacomelli; Yahaira Naaldijk; Laura Sardá-Arroyo; Maria C B Gonçalves; Juliana Corrêa-Velloso; Micheli M Pillat; Héllio D N de Souza; Henning Ulrich
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.